Terkko Navigator / -/ Feeds / "j urol "

Corrigendum to “Diagnostic Accuracy of Novel Urinary Biomarker Tests in Non–muscle-invasive Bladder Cancer: A Systematic Review and Network Meta-analysis” [Eur Urol Oncol 2021;4:927–42]

Re: Lloyd P, Hong A, Furrer MA, et al. A comparative study of perioperative outcomes for 100 consecutive post-chemotherapy and primary robot assisted and open retroperitoneal lymph node dissections. World J Urol. 2021; DOI: 10.1007/s00345-021-03832-0

Re: Ekaterina Laukhtina, Sung Ryul Shim, Keiichiro Mori, et al. Diagnostic Accuracy of Novel Urinary Biomarker Tests in Non-muscle-invasive Bladder Cancer: A Systematic Review and Network Meta-analysis. Eur Urol Oncol 2021;4:927–42: Considerations fo

Re: Andrew Erickson, Alicia Hayes, Timothy Rajakumar, et al. A Systematic Review of Prostate Cancer Heterogeneity: Understanding the Clonal Ancestry of Multifocal Disease. Eur Urol Oncol 2021;4:358–69

Reply to Kenta Ushida, Miho Shimizu, and Ryo Momosaki’s Letter to the Editor re: Logan G. Briggs, Chanan Reitblat, Paul A. Bain, et al. Prehabilitation Exercise Before Urologic Cancer Surgery: A Systematic and Interdisciplinary Review. Eur Urol. In p

Re: Logan G. Briggs, Chanan Reitblat, Paul A. Bain, et al. Prehabilitation Exercise Before Urologic Cancer Surgery: A Systematic and Interdisciplinary Review. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2021.05.015: Strategies for Effective

Re: Trey Durdin, Alvin Goh, Eugene Pietzak. Can an Imaging-guided Pathway Replace the Current Paradigm for Muscle-invasive Bladder Cancer? Eur Urol 2021;80:16–7: Transurethral Resection of Bladder Tumor in Diagnosis of Muscle-invasive Bladder Cancer:

Re: Gottfrid Sjödahl, Johan Abrahamsson, Karin Holmsten, et al. Different Responses to Neoadjuvant Chemotherapy in Urothelial Carcinoma Molecular Subtypes. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2021.10.035: Neoadjuvant Chemotherapy Res

Re: How to Manage Patients with Suspected Upper Tract Urothelial Carcinoma in the Pandemic of COVID-19? Lee HY, Chan EOT, Li CC, et al Urol Oncol 2021;39:733.e11–6

Editorial Comment: Systematic Literature Review and Meta-Analysis of Sacral Neuromodulation (SNM) in Patients with Neurogenic Lower Urinary Tract Dys-function (nLUTD): Over 20 Years' Experience and Fu-ture Directions

Intravaginal eletrical stimulation for bladder training method

The combined effect of lifestyle intervention and antioxidant therapy on sperm DNA fragmentation and seminal oxidative stress in IVF patients: a pilot study

Single-use flexible ureteroscopes: update and perspective in developing countries. A narrative review

Reply from Authors re: Peter C. Albertsen. The Treatment Paradigm Shifts Again on Prostate Cancer. Eur Urol. In press. doi: 10.1016/j.eururo.2008.09.014.

Re: The True Incidence of Cryptorchidism in Denmark D. Cortes, E. M. Kjellberg, M. Breddam and J. Thorupj urol 2008; 179: 314-318.

Re: Does Previous Extracorporeal Shock Wave Lithotripsy Affect the Performance and Outcome of Percutaneous Nephrolithotomy? E. Yuruk, A. Tefekli, E. Sari, M. A. Karadag, A. Tepeler, M. Binbay and A. Y. Muslumanogluj urol 2009; 181: 663-667.

Reply from Authors re: Giuseppe Morgia. Does the Use of Silodosin to Treat Benign Prostatic Hyperplasia Really Offer Something New? Eur Urol. In press. doi:10.1016/j.eururo.2010.11.023.

Reply from Authors re: Guido Barbagli, Salvatore Sansalone, Massimo Lazzeri. Oral Mucosa and Urethroplasty: It's Time to Change. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2012.07.042: Oral Mucosa as a Reservoir of Human Papillomavirus: I

Reply from Authors re: Guido Barbagli, Salvatore Sansalone, Massimo Lazzeri. Oral Mucosa and Urethroplasty: It's Time to Change. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2012.07.042: Oral Mucosa as a Reservoir of Human Papillomavirus: I

Reply from Authors re: Nicolas Mottet Intermittent Androgen Deprivation in Prostate Cancer: Is Everything So Clear? Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2012.08.004: Intermittent Androgen Deprivation in Advanced Prostate Cancer: An

Reply from Authors re: Jonathan Bergman, Mark S. Litwin. The Henderson-Hasselbalch Equation for Urologists. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2012.12.021: Health-related Quality-of-life Scores from the Finnish Trial of Screening

Reply from Authors re: Behfar Ehdaie, Karim A. Touijer. 5-Alpha Reductase Inhibitors in Prostate Cancer: From Clinical Trials to Clinical Practice. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2012.12.035: 5-Alpha Reductase Inhibitors in Pr

Reply from Authors re: Jonathan Bergman, Mark S. Litwin. The Henderson-Hasselbalch Equation for Urologists. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2012.12.021: Health-related Quality-of-life Scores from the Finnish Trial of Screening

Re: Fatemeh Seyednasrollah, Mehrad Mahmoudian, Liisa Rautakorpi, et al. How Reliable are Trial-based Prognostic Models in Real-world Patients with Metastatic Castration-resistant Prostate Cancer? Eur Urol. 2017;71:838-40.

Re: Fatemeh Seyednasrollah, Mehrad Mahmoudian, Liisa Rautakorpi, et al. How Reliable are Trial-based Prognostic Models in Real-world Patients with Metastatic Castration-resistant Prostate Cancer? Eur Urol. 2017;71:838-40.

Corrigendum re "Docetaxel Versus Surveillance After Radical Radiotherapy for Intermediate- or High-risk Prostate Cancer-Results from the Prospective, Randomised, Open-label Phase III SPCG-13 Trial" [Eur Urol 2019;76:823-30]

Reply to Laurence Klotz’s Letter to the Editor re: Jeremy Yeun-Chun Teoh, Daniele Castellani, Claudia Mercader, et al. A Quantitative Analysis Investigating the Prevalence of “Manels” in Major Urology Meetings. Eur Urol 2021;80:442–9. Eur Urol 2021;8

Corrigendum re “Docetaxel Versus Surveillance After Radical Radiotherapy for Intermediate- or High-risk Prostate Cancer—Results from the Prospective, Randomised, Open-label Phase III SPCG-13 Trial” [Eur Urol 2019;76:823–30]

Re: Marcus J. Drake, Amanda L. Lewis, Grace J. Young, et al. Diagnostic Assessment of Lower Urinary Tract Symptoms in Men Considering Prostate Surgery: A Noninferiority Randomised Controlled Trial of Urodynamics in 26 Hospitals. Eur Urol. In press. h

Re: Kathrin Meisterhofer, Sereina Herzog, Karin A. Strini, Luca Sebastianelli, Ricarda Bauer, Orietta Dalpiaz. Male Slings for Postprostatectomy Incontinence: A Systematic Review and Meta-analysis. Eur Urol Focus 2020;6:575–92

Re: Impact of Nocturia on Mortality: The Nagahama Study: S. Funada, Y. Tabara, K. Setoh, H. Negoro, S. Akamatsu, T. Yoshino, K. Yoshimura, N. Watanabe, T. A. Furukawa, F. Matsuda and O. Ogawa j urol 2020; doi: 10.1097/JU.0000000000001138

Re: Hiten D. Patel, Farzana A. Faisal, Bruce J. Trock, et al. Effect of Pharmacologic Prophylaxis on Venous Thromboembolism After Radical Prostatectomy: The PREVENTER Randomized Clinical Trial. Eur Urol 2020;78:360–8

Corrigendum to “A standard operating technique to facilitate early return of urinary continence after robotic prostatectomy outcomes of a consensus meeting of experts with experience of over 30,000 cases” [Eur Urol Suppl 2017;16;e2301–2]

Re: Hiten D. Patel, Farzana A. Faisal, Bruce J. Trock, et al. Effect of Pharmacologic Prophylaxis on Venous Thromboembolism After Radical Prostatectomy: The PREVENTER Randomized Clinical Trial. Eur Urol 2020;78:360–8

Re: Alfonso Gómez de Liaño Lista, Nick van Dijk, Guillermo de Velasco Oria de Rueda, et al. Clinical Outcome After Progressing to Frontline and Second-line Anti–PD-1/PD-L1 in Advanced Urothelial Cancer. Eur Urol 2020;77:269–76: Progression and Hyperp

Re: Silke Gillessen, Gerhardt Attard, Tomasz M. Beer, et al. Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. Eur Urol. 2020;77: 508–47 https://doi.org/10.1016/j.eururo.2020.01.01

Re: Lisa Moris, Marcus G. Cumberbatch, Thomas Van den Broeck, et al. Benefits and Risks of Primary Treatments for High-risk Localized and Locally Advanced Prostate Cancer: An International Multidisciplinary Systematic Review. Eur Urol 2020;77:614–27

Reply to Alireza Ghoreifi and Hooman Djaladat’s Letter to the Editor re: Fredrik Liedberg, Petter Kollberg, Marie Allerbo, et al. Preventing Parastomal Hernia After Ileal Conduit by the Use of a Prophylactic Mesh: A Randomised Study. Eur Urol. In pre

Re: Fredrik Liedberg, Petter Kollberg, Marie Allerbo, et al. Preventing Parastomal Hernia After Ileal Conduit by the Use of a Prophylactic Mesh: A Randomised Study. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.07.033

Re: Long-Term Outcomes of Active Surveillance for Prostate Cancer: The Memorial Sloan Kettering Cancer Center Experience. J Urol. 2020;203(6):1122-7.

Re: Beatriz Goulao, Sonya Carnell, Jing Shen, et al. Surgical Treatment for Recurrent Bulbar Urethral Stricture: A Randomised Open-label Superiority Trial of Open Urethroplasty Versus Endoscopic Urethrotomy (the OPEN Trial). Eur Urol 2020;78:572–80

Re: Madhuri Koti, Molly A. Ingersoll, Shilpa Gupta, et al. Sex Differences in Bladder Cancer Immunobiology and Outcomes: A Collaborative Review with Implications for Treatment. Eur Urol Oncol 2020;3:622–30

Letter to the editor re: Worsening disability status in multiple sclerosis predicts urologic complications. Int Urol Nephrol. May; 52(5):859–863. doi: 10.1007/s11255-020-02381-6. Epub 2020 Jan 25 by Abello et al

Re: Russell E.N. Becker, Alexa R. Meyer, Aaron Brant, et al. Clinical Restaging and Tumor Sequencing are Inaccurate Indicators of Response to Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer. Eur Urol. In press. https://doi.org/10.1016/j.e

Re: Hugh Mostafid, Ashish M. Kamat, Siamak Daneshmand, et al. Best Practices to Optimise Quality and Outcomes of Transurethral Resection of Bladder Tumours. Eur Urol Oncol. In press. https://doi.org/10.1016/j.euo.2020.06.010